PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Research and Development, Nanogen Pharmaceutical Biotechnology Joint Stock Company (JSC), Ho Chi Minh City, Vietnam.\', \'Department of Virology, National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.766112
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34938290
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all